Cited by 717Pancreatic and Hepatic Oncology ResearchCancer Genomics and DiagnosticsPancreatitis Pathology and Treatment

The DOI matches its Crossref record; 185 of the 185 references it cites were found in a registry or an index.

Pancreatic Cancer

Open access

Maitra, Anirban, Hruban, Ralph H.·2008·Annual Review of Pathology: Mechanisms of Disease

DOI 10.1146/annurev.pathmechdis.3.121806.154305PMC PMC2666336

Open this paper in CoChat — free account

Abstract

The past two decades have witnessed an explosion in our understanding of pancreatic cancer, and it is now clear that pancreatic cancer is a disease of inherited (germ-line) and somatic gene mutations. The genes mutated in pancreatic cancer include KRAS2, p16/CDKN2A, TP53, and SMAD4/DPC4, and these are accompanied by a substantial compendium of genomic and transcriptomic alterations that facilitate cell cycle deregulation, cell survival, invasion, and metastases. Pancreatic cancers do not arise de novo, and three distinct precursor lesions have been identified. Experimental models of pancreatic cancer have been developed in genetically engineered mice, which recapitulate the multistep progression of the cognate human disease. Although the putative cell of origin for pancreatic cancer remains elusive, minor populations of cells with stem-like properties have been identified that appear responsible for tumor initiation, metastases, and resistance of pancreatic cancer to conventional therapies.

Integrity signals

Registry

Crossref · 10.1146/annurev.pathmechdis.3.121806.154305

Cites

185 of 185 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

We couldn’t retrieve this paper’s full text, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

1 retracted

Retracted: Notch‐1 down‐regulation by curcumin is associated with the inhibition of cell growth and the induction of apoptosis in pancreatic cancer cells
Wang, Z., Zhang, Y., Banerjee, S., Li, Y., & Sarkar, F. H. (2006) · Cancer · doi:10.1002/cncr.21904 · Cited by 263
Retracted
Prospective identification of tumorigenic breast cancer cells
Al‐Hajj, M., Wicha, M. S., Benito‐Hernández, A., Morrison, S. J., & Clarke, M. F. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0530291100 · Cited by 10,579
Stem cells, cancer, and cancer stem cells
Reya, T., Morrison, S. J., Clarke, M. F., & Weissman, I. L. (2001) · Nature · doi:10.1038/35102167 · Cited by 9,738
MicroRNA expression profiles classify human cancers
Lü, J., Getz, G. A., Miska, E. A., Alvarez-Saavedra, E., Lamb, J., Peck, D., Sweet-Cordero, A., Ebert, B. L., Mak, R. H., Ferrando, A. A., et al. (2005) · Nature · doi:10.1038/nature03702 · Cited by 9,637
1969 Cancer Facts and Figures
(1968) · American Association of Industrial Nurses Journal · doi:10.1177/216507996801601208 · Cited by 8,811
Human acute myeloid leukemia is organized as a hierarchy that originates from a primitive hematopoietic cell
Bonnet, D. A., & Dick, J. E. (1997) · Nature Medicine · doi:10.1038/nm0797-730 · Cited by 7,197
Glioma stem cells promote radioresistance by preferential activation of the DNA damage response
Bao, S., Wu, Q., McLendon, R. E., Hao, Y., Shi, Q., Hjelmeland, A. B., Dewhirst, M. W., Bigner, D. D., & Rich, J. N. (2006) · Nature · doi:10.1038/nature05236 · Cited by 6,517
Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial.
Burris, H. A., Moore, M. J., Andersen, J., Green, M. R., Rothenberg, M. L., Modiano, M., Cripps, M. C., Portenoy, R. K., Storniolo, A. M., Tarassoff, P. G., et al. (1997) · Journal of Clinical Oncology · doi:10.1200/jco.1997.15.6.2403 · Cited by 5,895
A microRNA expression signature of human solid tumors defines cancer gene targets
Volinia, S., Calin, G. A., Liu, C.-G., Ambs, S., Cimmino, A., Petrocca, F., Visone, R., Iorio, M., Roldo, C., Ferracin, M., et al. (2006) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0510565103 · Cited by 5,697
A cell initiating human acute myeloid leukaemia after transplantation into SCID mice
Lapidot, T., Sirard, C., Vormoor, J., Murdoch, B., Hoang, T., Caceres-Cortes, J., Minden, M., Paterson, B., Caligiuri, M. A., & Dick, J. E. (1994) · Nature · doi:10.1038/367645a0 · Cited by 4,783

Show all 185 references

Research works printed but not linked: 24

10.1001/jama.1995.03520440059037 · DOI
Goggins M, 1996, Cancer Res., 56, 5360
de vos tot Nederveen Cappel WH, 2003, Clin. Cancer Res., 9, 3598
Goggins M, 1998, Am. J. Pathol., 152, 1501
Hruban RH, 2006, Tumors of the Pancreas
Iacobuzio-Donahue CA, 2003, Cancer Res., 63, 8614
Argani P, 2001, Cancer Res., 61, 4320
Argani P, 2001, Clin. Cancer Res., 7, 3862
Moskaluk CA, 1997, Cancer Res., 57, 2140
Altomare DA, 2003, J. Cell Biochem., 88, 470
Schutte M, 1997, Cancer Res., 57, 3126
Redston MS, 1994, Cancer Res., 54, 3025
Wilentz RE, 2000, Cancer Res., 60, 2002
Schutte M, 1996, Cancer Res., 56, 2527
Goggins M, 1998, Cancer Res., 58, 5329
Sato N, 2003, Cancer Res., 63, 4158
Ryu B, 2002, Cancer Res., 62, 819
Deramaudt T, 2005, Biochim. Biophys. Acta, 1756, 97
Brembeck FH, 2003, Cancer Res., 63, 2005
Ryu B, 2002, Cancer Res., 62, 819
Zhou W, 1998, Cancer Epidemiol. Biomark. Prev., 7, 109
Yamada T, 1998, Clin. Cancer Res., 4, 1527
Yamamoto H, 2001, Cancer Res., 61, 3139
van der Heijden MS, 2003, Cancer Res., 63, 2585

Sorted by citations

Items 401–500 of 717

Pancreatic cancer-improved care achievable
Buanes, T. A. (2014) · World Journal of Gastroenterology · doi:10.3748/wjg.v20.i30.10405 · Cited by 19
Phosphorylation Regulates CAP1 (Cyclase-Associated Protein 1) Functions in the Motility and Invasion of Pancreatic Cancer Cells
Wu, H., Hasan, R., Zhang, H., Gray, J., Williams, D., Miller, M., Allen, F. M., Lee, V., Kelly, T. J., & Zhou, G.-L. (2019) · Scientific Reports · doi:10.1038/s41598-019-41346-3 · Cited by 19
FUNCTIONAL FOODS FOR PREVENTION AND TREATMENT OF CANCER
TIWARY, S., & Hussain, M. S. (2021) · Asian Journal of Pharmaceutical and Clinical Research · doi:10.22159/ajpcr.2021.v14i3.40426 · Cited by 19
Reliable Detection of Somatic Mutations for Pancreatic Cancer in Endoscopic Ultrasonography-Guided Fine Needle Aspirates with Next-Generation Sequencing: Implications from a Prospective Cohort Study
Habib, J. R., Zhu, Y., Yin, L., Javed, A. A., Ding, D., Teinor, J. A., Wright, M. J., Ali, S. Z., Burkhart, R. A., Burns, W. R., et al. (2021) · Journal of Gastrointestinal Surgery · doi:10.1007/s11605-021-05078-y · Cited by 19
Regulators of epithelial mesenchymal transition in pancreatic cancer
Hamada, S., Satoh, K., Masamune, A., & Shimosegawa, T. (2012) · Frontiers in Physiology · doi:10.3389/fphys.2012.00254 · Cited by 19
Poly(ADP-Ribose) Polymerases
Martínez‐Bosch, N., Fernández-Zapico, M. E., Navarro, P., & Yélamos, J. (2015) · American Journal Of Pathology · doi:10.1016/j.ajpath.2015.09.021 · Cited by 20
Silencing of TPD52 inhibits proliferation, migration, invasion but induces apoptosis of pancreatic cancer cells by deactivating Akt pathway
Wang, Z., Li, Y., Fan, L., Zhao, Q., Tan, B., Liu, R., & Li, F. (2019) · Neoplasma · doi:10.4149/neo_2019_190404n295 · Cited by 19
IMUP and GPRC5A: two newly identified risk score indicators in pancreatic ductal adenocarcinoma
Wei, R., Qi, G., Zeng, Z., Shen, N., Wang, Z., Shen, H., Gao, L., Song, C., Ma, W., & Wang, C. (2021) · Cancer Cell International · doi:10.1186/s12935-021-02324-w · Cited by 16
Exploring the Biology of Cancer-Associated Fibroblasts in Pancreatic Cancer
Bryce, A. S., Dreyer, S. B., Froeling, F. E. M., & Chang, D. K.-F. (2022) · Cancers · doi:10.3390/cancers14215302 · Cited by 19
Single-cell omics: a new perspective for early detection of pancreatic cancer?
Wang, Q., Šabanović, B., Awada, A., Reina, C., Aicher, A., Tang, J., & Heeschen, C. (2023) · European Journal of Cancer · doi:10.1016/j.ejca.2023.112940 · Cited by 19
Utilizing somatic mutation data from numerous studies for cancer research: proof of concept and applications
Amar, D., Izraeli, S., & Ron Shamir, A. (2017) · Oncogene · doi:10.1038/onc.2016.489 · Cited by 18
Prognostic value of loss of heterozygosity and sub-cellular localization of SMAD4 varies with tumor stage in colorectal cancer
Jia, X., Shanmugam, C., Paluri, R. K., Jhala, N. C., Behring, M. P., Katkoori, V. R., Sugandha, S. P., Bae, S., Samuel, T., & Manne, U. (2017) · Oncotarget · doi:10.18632/oncotarget.15560 · Cited by 18
Activation of TAp73 and Inhibition of TrxR by Verteporfin for Improved Cancer Therapy in TP53 Mutant Pancreatic Tumors
Acedo, P., Fernandes, A. P., & Zawacka‐Pankau, J. (2019) · Future Science OA · doi:10.4155/fsoa-2018-0082 · Cited by 18
FOLFIRINOX Versus Gemcitabine-based Therapy for Pancreatic Ductal Adenocarcinoma: Lessons from Patient-derived Cell Lines
Begg, S. K. S., Birnbaum, D. J., Clark, J. W., Mino-Kenudson, M. A., Wellner, U. F., Schilling, O., Lillemoe, K. D., Warshaw, A. L., Castillo, C. F. F.-D., & Liss, A. S. (2020) · Anticancer Research · doi:10.21873/anticanres.14355 · Cited by 18
Clinical Applications of Classical and Novel Biological Markers of Pancreatic Cancer
Pekarek, L., Fraile‐Μartinez, O., Montero, C. G., Sáez, M. A., Barquero-Pozanco, I., del Hierro-Marlasca, L., Castro-Martinez, P. D., Romero-Bazán, A., Álvarez-Mon, M. Á., Monserrat, J., et al. (2022) · Cancers · doi:10.3390/cancers14081866 · Cited by 18
The Fatal Attraction Between Pro-Prion and Filamin A: Prion As a Marker in Human Cancers
Sy, M., Li, C., Yu, S., & Xin, W. (2010) · Biomarkers in Medicine · doi:10.2217/bmm.10.14 · Cited by 18
pH-responsive targeted nanoparticles release ERK-inhibitor in the hypoxic zone and sensitize free gemcitabine in mutant K-Ras-addicted pancreatic cancer cells and mouse model
Dutta, D., Ray, P., De, A., Ghosh, A., Hazra, R. S., Ghosh, P., Banerjee, S., Díaz, F. J., Upadhyay, S. P., Quadir, M., et al. (2024) · PLoS ONE · doi:10.1371/journal.pone.0297749 · Cited by 17
Three‐dimensional genome structure and function
Liu, H., Tsai, H., Yang, M., Li, G., Bian, Q., Ding, G., Wu, D., & Dai, J. (2023) · MedComm · doi:10.1002/mco2.326 · Cited by 25
Targeting Defects in the Cellular DNA Damage Response for the Treatment of Pancreatic Ductal Adenocarcinoma
Schmitt, A., Feldmann, G., Zander, T., & Reinhardt, H. C. (2018) · Oncology Research and Treatment · doi:10.1159/000493401 · Cited by 18
MicroRNA-Regulated Signaling Pathways: Potential Biomarkers for Pancreatic Ductal Adenocarcinoma
Mortoglou, M., Wallace, D., Djordjević, A. B., Djordjevic, V. R., Arısan, E. D., & Onganer, P. U. (2021) · Stresses · doi:10.3390/stresses1010004 · Cited by 17
K‐RasV14I‐induced Noonan syndrome predisposes to tumour development in mice
Hernández‐Porras, I., Schuhmacher, A. J., Garcia‐Medina, R., Jiménez, B., Cañamero, M., de Martino, A., & Guerra, C. (2016) · The Journal of Pathology · doi:10.1002/path.4719 · Cited by 16
Cyclopamine increases the radiosensitivity of human pancreatic cancer cells by regulating the DNA repair signal pathway through an epidermal growth factor receptor-dependent pathway
Wu, X., Che, J., SUN, K.-K., Shen, X., Yang, D. W., Zhong, N., & Zhao, H. (2013) · Molecular Medicine Reports · doi:10.3892/mmr.2013.1605 · Cited by 16
Germline variants of ATG7 in familial cholangiocarcinoma alter autophagy and p62
Greer, S., Chen, J., Ogmundsdottir, M. H., Ayala, C. I., Lau, B. T., Delacruz, R. G. C., Sandoval, I. T., Kristjánsdóttir, S., Jones, D. A., Haslem, D. S., et al. (2022) · Scientific Reports · doi:10.1038/s41598-022-13569-4 · Cited by 16
An Overview of Genetic Changes and Risk of Pancreatic Ductal Adenocarcinoma
Sarnecka, A. K., Zagozda, M., & Durlik, M. (2016) · Journal of Cancer · doi:10.7150/jca.15323 · Cited by 16
Inhibitors of telomerase and poly(ADP-ribose) polymerases synergize to limit the lifespan of pancreatic cancer cells
Burchett, K. M., Etekpo, A., Batra, S. K., Yan, Y., & Ouellette, M. M. (2017) · Oncotarget · doi:10.18632/oncotarget.19410 · Cited by 16
Inactivation of APC Induces CD34 Upregulation to Promote Epithelial-Mesenchymal Transition and Cancer Stem Cell Traits in Pancreatic Cancer
Hsieh, M.-J., Chiu, T., Lin, Y. C., Weng, C., Weng, Y., Hsiao, C., & Cheng, K. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21124473 · Cited by 17
Radiation-Induced Autophagy in Human Pancreatic Cancer Cells is Critically Dependent on G2 Checkpoint Activation: A Mechanism of Radioresistance in Pancreatic Cancer
Suzuki, M., Anko, M., Ohara, M., Matsumoto, K., & Hasegawa, S. (2021) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2021.04.001 · Cited by 16
Chromosome instability and carcinogenesis: Insights from murine models of human pancreatic cancer associated with BRCA2 inactivation
Cassidy, L. D., Liau, S., & Venkitaraman, A. R. (2013) · Molecular Oncology · doi:10.1016/j.molonc.2013.10.005 · Cited by 16
Role of anti-stromal polypharmacy in increasing survival after pancreaticoduodenectomy for pancreatic ductal adenocarcinoma
Tingle, S. J. (2015) · World Journal of Gastrointestinal Pathophysiology · doi:10.4291/wjgp.v6.i4.235 · Cited by 15
MiRNAs directly targeting the key intermediates of biological pathways in pancreatic cancer
Sarwar, A., Wang, B., Su, Q., & Zhang, Y. (2020) · Biochemical Pharmacology · doi:10.1016/j.bcp.2020.114357 · Cited by 14
Inhibiting CDK4/6 in pancreatic ductal adenocarcinoma via microRNA-21
Mortoglou, M., Miralles, F., Mould, R. R., Sengupta, D., & Onganer, P. U. (2023) · European Journal of Cell Biology · doi:10.1016/j.ejcb.2023.151318 · Cited by 17
Tumor Stroma as a Therapeutic Target for Pancreatic Ductal Adenocarcinoma
Lee, D. U., Han, B. S., Jung, K. H., & Hong, S. (2024) · Biomolecules & Therapeutics · doi:10.4062/biomolther.2024.029 · Cited by 16
Treatment of experimental pancreatic cancer with 213-Bismuth-labeled chimeric antibody to single-strand DNA
Bryan, R. A., Jiang, Z., Jandl, T. A., Strauss, J., Koba, W. R., Onyedika, C., Morgenstern, A., Bruchertseifer, F., Epstein, A. L., & Dadachova, E. (2014) · Expert Review of Anticancer Therapy · doi:10.1586/14737140.2014.952285 · Cited by 15
PARP Inhibitors in Pancreatic Cancer: From Phase I to Plenary Session
Patel, R., Fein, D. E. C., Bernabe, C., Do, K. J., & Saif, M. W. (2019) · Pancreas - Open Journal · doi:10.17140/poj-3-e011 · Cited by 15
Evaluation of biomarkers, genetic mutations, and epigenetic modifications in early diagnosis of pancreatic cancer
Rah, B., Banday, M. A., Bhat, G. R., Shah, O. J., Jeelani, H., Kawoosa, F., Yousuf, T., & Afroze, D. (2021) · World Journal of Gastroenterology · doi:10.3748/wjg.v27.i36.6093 · Cited by 15
Id3 modulates cellular localization of bHLH Ptf1‐p48 protein
Dufresne, M., Clerc, P., Dieng, M., Edir, A., Couvelard, A., Delisle, M., Fourmy, D., & Gigoux, V. (2010) · International Journal of Cancer · doi:10.1002/ijc.25668 · Cited by 15
Complex regulation of cell-cycle inhibitors by Fbxw7 in mouse embryonic fibroblasts
Masuda, K., Ishikawa, Y., Onoyama, I., Unno, M., de Alborán, I. M., Nakayama, K., & Nakayama, K. (2009) · Oncogene · doi:10.1038/onc.2009.469 · Cited by 15
Mining the Human Proteome
Yang, J., Roy, R., Jedinak, A., & Moses, M. A. (2015) · The Cancer Journal · doi:10.1097/ppo.0000000000000139 · Cited by 15
Stem Cells in the Exocrine Pancreas during Homeostasis, Injury, and Cancer
Lodestijn, S. C., van Neerven, S. M., Vermeulen, L., & Bijlsma, M. F. (2021) · Cancers · doi:10.3390/cancers13133295 · Cited by 17
Parp‐1 genetic ablation in Ela–myc mice unveils novel roles for Parp‐1 in pancreatic cancer
Martínez‐Bosch, N., Iglesias, M., Munné‐Collado, J., Martínez, C. M., Moreno, M., Guerra, C. E., Yélamos, J., & Navarro, P. (2014) · The Journal of Pathology · doi:10.1002/path.4384 · Cited by 17
Interactions of Everolimus and Sorafenib in Pancreatic Cancer Cells
Pawaskar, D. K., Straubinger, R. M., Fetterly, G. J., Ma, W. W., & Jusko, W. J. (2012) · The AAPS Journal · doi:10.1208/s12248-012-9417-7 · Cited by 15
Increased mutant KRAS gene dosage drives pancreatic cancer progression: evidence for wild-type KRAS as a tumor suppressor?
Kent, O. A. (2018) · HepatoBiliary Surgery and Nutrition · doi:10.21037/hbsn.2018.07.03 · Cited by 15
Team work and cytopathology molecular diagnosis of solid pancreatic lesions
Fabbri, C., Gibiino, G., Fornelli, A., Cennamo, V., Grifoni, D., Visani, M., Acquaviva, G., Fassan, M., Fiorino, S., Giovanelli, S., et al. (2017) · Digestive Endoscopy · doi:10.1111/den.12845 · Cited by 14
PTGES Expression Is Associated with Metabolic and Immune Reprogramming in Pancreatic Ductal Adenocarcinoma
Murthy, D., & Attri, K. S. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24087304 · Cited by 14
Clinical and Preclinical Targeting of Oncogenic Pathways in PDAC: Targeted Therapeutic Approaches for the Deadliest Cancer
Jiménez, D. J., Javed, A., Rubio‐Tomás, T., Seye-Loum, N., & Barceló, C. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25052860 · Cited by 14
Pancreatic Adenocarcinoma
Amin, S., & DiMaio, C. J. (2015) · Springer eBooks · doi:10.1007/978-3-319-19677-0_2 · Cited by 14
Standardized Peptidome Profiling of Human Serum for the Detection of Pancreatic Cancer
Zapico‐Muñiz, E., Viladrich, A. F., Rico-Santana, N., González‐Sastre, F., & Móra, J. (2010) · Pancreas · doi:10.1097/mpa.0b013e3181dfcbe5 · Cited by 14
URG11 predicts poor prognosis of pancreatic cancer by enhancing epithelial–mesenchymal transition-driven invasion
Peng, W. J., Zhang, J., & Liu, J. (2014) · Medical Oncology · doi:10.1007/s12032-014-0064-y · Cited by 14
Computer-aided assessment of the extra-cellular matrix during pancreatic carcinogenesis: a pilot study
Grizzi, F., Fiorino, S., Qehajaj, D., Fornelli, A., Russo, C., de Biase, D., Masetti, M., Mastrangelo, L., Zanello, M., Lombardi, R., et al. (2019) · Journal of Translational Medicine · doi:10.1186/s12967-019-1817-3 · Cited by 14
Selection of patients with pancreatic adenocarcinoma who may benefit from radiotherapy
Jan, I., & Ch’ang, H.-J. (2023) · Radiation Oncology · doi:10.1186/s13014-023-02328-y · Cited by 13
Fundamental insights and molecular interactions in pancreatic cancer: Pathways to therapeutic approaches
Gu, M., Liu, Y., Xin, P., Guo, W., Zhao, Z., Xu, Y., Ma, R., Jiao, T., & Zheng, W. (2024) · Cancer Letters · doi:10.1016/j.canlet.2024.216738 · Cited by 13
Cyclooxygenase-2 Influences Response to Cotargeting of MEK and CDK4/6 in a Subpopulation of Pancreatic Cancers
Maust, J. D., Frankowski-McGregor, C. L., Bankhead, A., Simeone, D. M., & Sebolt, J. S. (2018) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-18-0082 · Cited by 12
p38 MAPK in Pancreatic Cancer: Finding a Protective Needle in the Haystack
Korc, M. (2014) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-14-1543 · Cited by 13
MicroRNA‑203‑3p inhibits the proliferation, invasion and migration of pancreatic cancer cells by downregulating fibroblast growth factor 2
Fu, X., Zhao, H., Chen, C.-Z., Wang, K., Gao, F., Tian, Y.-Z., Li, H.-Y., & Zhao, H. (2021) · Oncology Letters · doi:10.3892/ol.2021.12887 · Cited by 13
Progression of Chronic Pancreatitis to Pancreatic Cancer
Rashid, S., Singh, N., Gupta, S., Rashid, S., Nalika, N., Sachdev, V., Bal, C. S., Gupta, S. D., Chauhan, S. S., & Saraya, A. (2018) · Pancreas · doi:10.1097/mpa.0000000000000975 · Cited by 13
Notch Signaling: Where Pancreatic Cancer and Differentiation Meet?
Jean–Paul De La, O., & Murtaugh, L. C. (2009) · Gastroenterology · doi:10.1053/j.gastro.2009.03.022 · Cited by 13
Clinical Application of Liquid Biopsy in Pancreatic Cancer: A Narrative Review
Ramírez‐Maldonado, E., Gordo, S. L., Branco, R. P. M., Pavel, M.-C., Estalella, L., Llàcer-Millán, E., Guerrero, M. A., López-Gordo, E., Memba, R., & Jorba, R. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25031640 · Cited by 12
Inhibition of P21-activated kinases 1 and 4 synergistically suppresses the growth of pancreatic cancer by stimulating anti-tumour immunity
Ma, Y., Dumesny, C., Dong, L., Ang, C., Asadi, K., Zhan, Y., Nikfarjam, M., & He, H. (2024) · Cell Communication and Signaling · doi:10.1186/s12964-024-01670-2 · Cited by 12
Identification and analysis of pancreatic intraepithelial neoplasia: opportunities and challenges
Pian, L.-L., Song, M.-H., Wang, T., Qi, L., Peng, T.-L., & Xie, K.-P. (2025) · Frontiers in Endocrinology · doi:10.3389/fendo.2024.1401829 · Cited by 15
A novel methylation signature predicts inferior outcome of patients with PDAC
Gu, M., Sun, J., Zhang, S., Chen, J., Wang, G., Ju, S., & Wang, X. (2021) · Aging · doi:10.18632/aging.202347 · Cited by 12
Pancreatic Cancer: Recent Progress of Drugs in Clinical Trials
Zhang, Z., Song, J., Xie, C., Pan, J., Lu, W., & Liu, M. (2021) · The AAPS Journal · doi:10.1208/s12248-021-00556-2 · Cited by 12
A 67-Year-Old Woman with BRCA 1 Mutation Associated with Pancreatic Adenocarcinoma
Lowery, M. A., Shah, M. A., Smyth, E. C., Epstein, A. S., Segal, A., Rosengarten, O. S., Isacson, R., Drukker, L., Keinan, A., Rachkiman, M., et al. (2010) · Journal of Gastrointestinal Cancer · doi:10.1007/s12029-010-9197-1 · Cited by 12
Anticancer activity of HS-527, a novel inhibitor targeting PI3-kinase in human pancreatic cancer cells
Ryu, Y.-L., Jung, K. H., Son, M. K., YAN, H. H., Kim, S. J., Shin, S., Hong, S., & Hong, S. (2014) · Cancer Letters · doi:10.1016/j.canlet.2014.07.001 · Cited by 12
Manganese superoxide dismutase expression is negatively associated with microRNA-301a in human pancreatic ductal adenocarcinoma
Pandit, H., Zhang, W., Li, Y., Agle, S. C., Li, X., Li, S. P., Cui, G., Li, Y., & Martin, R. C. G. (2015) · Cancer Gene Therapy · doi:10.1038/cgt.2015.46 · Cited by 12
High ARHGEF2 (GEF-H1) Expression is Associated with Poor Prognosis Via Cell Cycle Regulation in Patients with Pancreatic Cancer
Nakao, Y., Nakagawa, S., Yamashita, Y., Umezaki, N., Okamoto, Y., Ogata, Y., Yasuda‐Yoshihara, N., Itoyama, R., Yusa, T., Yamashita, K., et al. (2021) · Annals of Surgical Oncology · doi:10.1245/s10434-020-09383-9 · Cited by 14
Triptolide augments the effects of 5-lipoxygenase RNA interference in suppressing pancreatic tumor growth in a xenograft mouse model
Ding, X., Zhou, X., Zhang, H., Qing, J., Qiang, H., & Zhou, G. (2011) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-011-1698-5 · Cited by 12
miRNAs as Diagnostic and Prognostic Biomarkers in Pancreatic Ductal Adenocarcinoma and Its Precursor Lesions: A Review
Alemar, B., Gregório, C., & Ashton‐Prolla, P. (2015) · Biomarker Insights · doi:10.4137/bmi.s27679 · Cited by 12
Synthesis of new tricyclic thiolactams as potent antitumor agent for pancreatic cancer
Okada, T., Minehira, D., Takada, M., Urata, H., Kato, A., Adachi, I., Kurashima, Y., Kaji, S., Ogura, T., Chiba, S., et al. (2016) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2016.04.035 · Cited by 12
In Vitro Measurement and Mathematical Modeling of Thermally-Induced Injury in Pancreatic Cancer Cells
Chamani, F., Pyle, M. M., Shrestha, T. B., Šebek, J., Bossmann, S. H., Basel, M. T., Sheth, R. A., & Prakash, P. (2023) · Cancers · doi:10.3390/cancers15030655 · Cited by 11
Review and Application of Integrin Alpha v Beta 6 in the Diagnosis and Treatment of Cholangiocarcinoma and Pancreatic Ductal Adenocarcinoma
Lian, Y., Zeng, S., Wen, S., Zhao, X., Fang, C., & Zeng, N. (2023) · Technology in Cancer Research & Treatment · doi:10.1177/15330338231189399 · Cited by 12
NEMO/NF-κB signaling functions as a double-edged sword in PanIN formation versus progression to pancreatic cancer
Tsesmelis, M., Büttner, U. F. G., Gerstenlauer, M., Manfras, U., Tsesmelis, K., Du, Z., Sperb, N., Weissinger, S. E., Möller, P., Barth, T. F. E., et al. (2024) · Molecular Cancer · doi:10.1186/s12943-024-01989-x · Cited by 11
Reprogramming tumor-associated macrophages with lipid nanosystems reduces PDAC tumor burden and liver metastasis
Palencia‐Campos, A., Ruíz-Cañas, L., Abal-Sanisidro, M., López-Gil, J. C., Batres-Ramos, S., Saraiva, S. M., Yagüe, B., Navarro, D., Alcalá, S., Rubiolo, J. A., et al. (2024) · Journal of Nanobiotechnology · doi:10.1186/s12951-024-03010-5 · Cited by 11
Multi-omic biomarker panel in pancreatic cyst fluid and serum predicts patients at a high risk of pancreatic cancer development
Kane, L. E., Mellotte, G. S., Mylod, E., Dowling, P., Marcone, S., Scaife, C., Kenny, E. M., Henry, M. A., Meleady, P., Ridgway, P. F., et al. (2025) · Scientific Reports · doi:10.1038/s41598-024-83742-4 · Cited by 12
Pancreatic Safety of Newer Incretin-Based Therapies: Are the “-tides” Finally Turning?
Devaraj, S., & Maitra, A. (2014) · Diabetes · doi:10.2337/db14-0545 · Cited by 11
Self-citation
Targeting Epithelial Mesenchymal Plasticity in Pancreatic Cancer: A Compendium of Preclinical Discovery in a Heterogeneous Disease
Monkman, J. H., Thompson, E. W., & Nagaraj, S. H. (2019) · Cancers · doi:10.3390/cancers11111745 · Cited by 12
A pharmacognostic approach for mitigating pancreatic cancer: emphasis on herbal extracts and phytoconstituents
Gupta, S., Kumar, A., & Tejavath, K. K. (2021) · Future Journal of Pharmaceutical Sciences · doi:10.1186/s43094-021-00246-y · Cited by 11
Pathology review of proliferative lesions of the exocrine pancreas in two chronic feeding studies in rats with ammonium perfluorooctanoate
Rae, J. M. C., Frame, S. R., Kennedy, G. L., Butenhoff, J. L., & Chang, S. (2014) · Toxicology Reports · doi:10.1016/j.toxrep.2014.04.005 · Cited by 11
Leveraging Mechanisms Governing Pancreatic Tumorigenesis To Reduce Pancreatic Cancer Mortality
Donahue, T. R., & Dawson, D. W. (2016) · Trends in Endocrinology and Metabolism · doi:10.1016/j.tem.2016.06.009 · Cited by 11
Murine Models of Pancreatitis Leading to the Development of Pancreatic Cancer
Leal, A. S., & Liby, K. T. (2018) · Current Protocols in Pharmacology · doi:10.1002/cpph.48 · Cited by 11
A Screen for Extracellular Signal-Regulated Kinase-Primed Glycogen Synthase Kinase 3 Substrates Identifies the p53 Inhibitor iASPP
Woodard, C. L., Liao, G., Goodwin, C. R., Hu, J., Xie, Z., dos Reis, T. F., Newman, R. H., Rho, H., Qian, J. X., Zhu, H., et al. (2015) · Journal of Virology · doi:10.1128/jvi.01072-15 · Cited by 11
The pancreatic niche inhibits the effectiveness of sunitinib treatment of pancreatic cancer
Martínez‐Bosch, N., Guerrero, P. E., Moreno, M., José, A., Iglesias, M., Munné‐Collado, J., Anta, H., Gibert, J., Orozco, C. A., Vinaixa, J., et al. (2016) · Oncotarget · doi:10.18632/oncotarget.10199 · Cited by 11
Unraveling and targeting RAS-driven metabolic signaling for therapeutic gain
DeLiberty, J. M., Robb, R. N., Gates, C. E., & Bryant, K. L. (2022) · Advances in cancer research · doi:10.1016/bs.acr.2021.07.010 · Cited by 10
Integrated genomic analysis to identify druggable targets for pancreatic cancer
Mugiyanto, E., Adikusuma, W., Irham, L. M., Huang, W., Chang, W., & Kuo, C.-N. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.989077 · Cited by 12
PAK in Pancreatic Cancer-Associated Vasculature: Implications for Therapeutic Response
Ansardamavandi, A., Nikfarjam, M., & He, H. Z. (2023) · Cells · doi:10.3390/cells12232692 · Cited by 10
A PAUF-neutralizing antibody targets both carcinoma and endothelial cells to impede pancreatic tumor progression and metastasis
Kim, S. J., Chang, S., Lee, Y., Kim, N. Y., Hwang, Y., Min, H. J., Yoo, K.-S., Park, E. H., Kim, S., Chung, Y.-H., et al. (2014) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2014.10.056 · Cited by 10
Co-dependency between KRAS addiction and ARHGEF2 promotes an adaptive escape from MAPK pathway inhibition
Kent, O. A., Sandí, M. J., & Rottapel, R. K. (2017) · Small GTPases · doi:10.1080/21541248.2017.1337545 · Cited by 11
Socioeconomic inequalities in pancreatic cancer incidence in Canada: evidence from Cancer Registry data
Anthes, L. E., & Hajizadeh, M. (2020) · Journal of Public Health · doi:10.1007/s10389-020-01360-6 · Cited by 10
Development of gemcitabine-resistant patient-derived xenograft models of pancreatic ductal adenocarcinoma
Miller, A. L., Garcia, P. L., Gamblin, T. L., Vance, R. B., & Yoon, K. J. (2020) · Cancer Drug Resistance · doi:10.20517/cdr.2020.35 · Cited by 10
Molecular Targeted Positron Emission Tomography Imaging and Radionuclide Therapy of Pancreatic Ductal Adenocarcinoma
Poels, T. T., Vuijk, F. A., de Geus‐Oei, L., Vahrmeijer, A. L., Oprea‐Lager, D. E., & Swijnenburg, R. (2021) · Cancers · doi:10.3390/cancers13246164 · Cited by 10
Repositioning of Old Drugs for Novel Cancer Therapies: Continuous Therapeutic Perfusion of Aspirin and Oseltamivir Phosphate with Gemcitabine Treatment Disables Tumor Progression, Chemoresistance, and Metastases
Qorri, B., Mokhtari, R. B., Harless, W. W., & Szewczuk, M. R. (2022) · Cancers · doi:10.3390/cancers14153595 · Cited by 11
The Many Faces of Wnt and Pancreatic Ductal Adenocarcinoma Oncogenesis
Weekes, C. D., & Winn, R. A. (2011) · Cancers · doi:10.3390/cancers3033676 · Cited by 10
Pancreatic Cancer Genomes: Toward Molecular Subtyping and Novel Approaches to Diagnosis and Therapy
Wood, L. D. (2013) · Molecular Diagnosis & Therapy · doi:10.1007/s40291-013-0043-6 · Cited by 10
Engrailed‐1 Promotes Pancreatic Cancer Metastasis
Xu, J., Roe, J., Lee, E., Tonelli, C., Ji, K. Y., Younis, O. W., Somervile, T. D. D., Yao, M. A., Milazzo, J. P., Tiriac, H., et al. (2023) · Advanced Science · doi:10.1002/advs.202308537 · Cited by 10
Targeting Apoptosis Signaling in Pancreatic Cancer
Fulda, S. (2011) · Cancers · doi:10.3390/cancers3010241 · Cited by 9
Altered expression of AXL receptor tyrosine kinase in gastrointestinal cancers: a promising therapeutic target
Pidkovka, N. A., & Belkhiri, A. (2023) · Frontiers in Oncology · doi:10.3389/fonc.2023.1079041 · Cited by 9
The epidemiology of pancreatic cancer
Lakatos, G., & Tulassay, Z. (2010) · Orvosi Hetilap · doi:10.1556/oh.2010.28986 · Cited by 9
Blocking SIAH Proteolysis, an Important K-RAS Vulnerability, to Control and Eradicate K-RAS-Driven Metastatic Cancer
Sciver, R. E. V., Njogu, M. M., Isbell, A. J., Odanga, J. J., Bian, M., Svyatova, E., van Reesema, L. L. S., Zheleva, V. P., Eisner, J., Bruflat, J. K., et al. (2016) · Elsevier eBooks · doi:10.1016/b978-0-12-803505-4.00012-6 · Cited by 9
Array comparative genomic hybridization of 18 pancreatic ductal adenocarcinomas and their autologous metastases
Rausch, V., Krieg, A. H., Camps, J., Behrens, B., Beier, M., Wangsa, D., Heselmeyer‐Haddad, K., Baldus, S. E., Knoefel, W. T., Ried, T., et al. (2017) · BMC Research Notes · doi:10.1186/s13104-017-2886-0 · Cited by 9
Pancreatic cancer with ovarian metastases: A case report and review of the literature
Wang, S., Zhu, L., Wu, H., Dai, M., & Zhao, Y.-P. (2020) · World Journal of Clinical Cases · doi:10.12998/wjcc.v8.i21.5380 · Cited by 9
Deletion of NEMO Inhibits EMT and Reduces Metastasis in KPC Mice
Tsesmelis, M., Tiwary, K., Steiger, K., Sperb, N., Gerstenlauer, M., Manfras, U., Maier, H. J., Hermann, P. C., Chan, L. K., & Wirth, T. (2021) · Cancers · doi:10.3390/cancers13184541 · Cited by 9

Authors: Maitra, A., & Hruban, R. H.
Affiliations: Johns Hopkins University (US)
ORCID: Maitra, Anirban
Hruban, Ralph H.
Venue: Annual Review of Pathology: Mechanisms of Disease
Publisher: Annual Reviews
Published: 2008-02-01
Volume: 3
Issue: 1
Pages: 157-188
ISSN: 1553-4006 (ISSN-L)
1553-4014
DOI: 10.1146/annurev.pathmechdis.3.121806.154305
PMC: PMC2666336
OpenAlex: W4211122150
Cited by: 707
References: 185
Citations by year: 2026: 16 · 2025: 10 · 2024: 31 · 2023: 29 · 2022: 55 · 2021: 46 · 2020: 46 · 2019: 39 · 2018: 43 · 2017: 42 · 2016: 41 · 2015: 53 · 2014: 59 · 2013: 48 · 2012: 32
FWCI: 3.60
Type: journal article
Language: en
Open access: green
www.ncbi.nlm.nih.gov
Locations: Annual Review of Pathology Mechanisms of Disease (publishedVersion)
PubMed (publishedVersion)
PubMed Central (acceptedVersion)
Funders: National Cancer Institute (R01CA113669, P50CA062924)
Topics: Health Sciences › Medicine › Oncology › Pancreatic and Hepatic Oncology Research
Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer Genomics and Diagnostics
Health Sciences › Medicine › Surgery › Pancreatitis Pathology and Treatment
Keywords: pancreatic cancer, germline mutations, somatic mutations, KRAS2, CDKN2A, TP53, genetic alterations, transcriptomic alterations, cell cycle dysregulation, metastasis, precursor lesions, genetically engineered mouse models, tumor progression, cancer stem cells, treatment resistance
MeSH terms: Animals, Disease Models, Animal, Humans, Pancreatic Neoplasms, Mice

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Pancreatic Cancer

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Citations

Cites

Cited by

Related

Metadata

Record

About these checks